Evidence map›Paper›PMID 42509226›Full record

ArticleMicrosystems & nanoengineering2026

Innovations in glaucoma treatment: development and testing of a novel self-adjustable implant for effective pressure regulation.

Soroush Rafiei, Julien Maxime Gerber, Stéphane Bigler, Adan Villamarin, Constantinos Stergiopulos, Nikolaos Stergiopulos

Abstract read
In one paragraph

Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Soroush RafieiLaboratory of Hemodynamics and Cardiovascular Technology (LHTC), Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland. soroush.rafiei@epfl.ch.
Julien Maxime GerberLaboratory of Hemodynamics and Cardiovascular Technology (LHTC), Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.
Stéphane BiglerLaboratory of Hemodynamics and Cardiovascular Technology (LHTC), Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.
Adan VillamarinRheon Medical SA, EPFL Innovation Park, Building B, Lausanne, Switzerland.
Constantinos StergiopulosRheon Medical SA, EPFL Innovation Park, Building B, Lausanne, Switzerland.
Nikolaos StergiopulosLaboratory of Hemodynamics and Cardiovascular Technology (LHTC), Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glaucoma drainage devices (GDDs) are widely used to lower intraocular pressure (IOP) and slow disease progression; however, existing designs often lack intrinsic protection against early postoperative hypotony, show limited adaptability to evolving distal outflow resistance during bleb maturation, and rely on bulky or complex components that constrain implantation and MRI compatibility. Here, we present a compact, fully passive, self-adjustable glaucoma implant designed to maintain IOP within the physiological range by dynamically modulating its hydraulic resistance without external control or postoperative adjustment. The device consists of a circular microvalve incorporating a thin, pre-stressed compliant membrane that responds to pressure conditions at the inlet and outlet. Valve performance was investigated using fully coupled fluid-structure interaction (FSI) simulations and parametric analyses, followed by fabrication and in vitro characterization, and ex vivo assessment of surgical feasibility in enucleated porcine eyes. The results demonstrate effective pressure regulation across physiologically relevant conditions, with mitigation of early hypotony and attenuation of pressure elevation under increasing downstream resistance. Ex vivo implantation confirmed ease of placement, appropriate anatomical fit, and compatibility with standard surgical workflows. Owing to its compact form factor, passive operation, and simplified, cost-effective design, the proposed implant addresses key limitations of current GDDs and shows strong potential for clinical translation.

Identifiers

PMID42509226
PMCPMC13407856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.